The gut microbiota metabolite butyrate mitigates MPTP / MPP + ‐induced Parkinson's disease by inhibiting the JAK2 / STAT3 signaling pathway
The Kaohsiung Journal of Medical Sciences · 2023-10 · 39 (10) · 1002-1010
DOI: 10.1002/kjm2.12745 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 09.10.2023. Verfasst von Li-Li Ji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jiangsu University Affiliated with Wujin Hospital (Wujin Clinical College of Xuzhou Medical University), Changzhou, China. Hauptthemen laut MEDLINE: Parkinson Disease, Gastrointestinal Microbiome, MPTP Poisoning, Neuroprotective Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changzhou Sci and Tech Program.
Abstract (Originalsprache)
Butyrate (BU), a gut microbiota‐derived metabolite, has been reported to play a neuroprotective role in Parkinson's disease (PD). However, the specific molecular mechanism of BU has not been fully interpreted. This work aimed to verify the protective effects of BU against MPTP/MPP + ‐induced neurotoxicity and explore the mechanisms involved. The results showed that BU protected against MPTP‐induced motor dysfunction and decreased tyrosine hydroxylase (TH) and dopamine transporter (DAT) levels. Additionally, BU pretreatment improved PC12 cell viability and reduced MPP + ‐induced PC12 cell apoptosis. BU treatment also attenuated MPP + ‐stimulated oxidative stress and inflammatory response in PC12 cells. Furthermore, BU inhibited MPTP/MPP + ‐induced hyperactivation of the JAK2/STAT3 signaling in mice and PC12 cells. Besides, a JAK2 agonist, Coumermycin A1 (C‐A1), substantially reversed BU‐mediated inhibition on JAK2/STAT3 phosphorylation in MPP + ‐challenged PC12 cells and abated BU‐induced repression on MPP + ‐triggered apoptosis, oxidative stress, and inflammatory response in PC12 cells. To sum up, BU might exert neuroprotective effects against MPP + /MPTP‐induced neurotoxicity by inactivating the JAK2/STAT3 signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Jiangsu University Affiliated with Wujin Hospital (Wujin Clinical College of Xuzhou Medical University), Changzhou, China.
- School of Basic Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Li-Hui Wang
Förderung
- Changzhou Sci and Tech Program
Zitieren
APA
Ji, L. L., Huang, T. T., Mao, L. L., Xu, Y. F., Chen, W. Y., Wang, W. W., & Wang, L. H. (2023). The gut microbiota metabolite butyrate mitigates MPTP / MPP + ‐induced Parkinson's disease by inhibiting the JAK2 / STAT3 signaling pathway. The Kaohsiung Journal of Medical Sciences, 39(10), 1002-1010. https://doi.org/10.1002/kjm2.12745
Vancouver
Ji LL, Huang TT, Mao LL, Xu YF, Chen WY, Wang WW, et al. The gut microbiota metabolite butyrate mitigates MPTP / MPP + ‐induced Parkinson's disease by inhibiting the JAK2 / STAT3 signaling pathway. The Kaohsiung Journal of Medical Sciences. 2023;39(10):1002-1010. doi:10.1002/kjm2.12745
BibTeX
@article{Ji2023,
author = {Ji, Li-Li and Huang, Ting-Ting and Mao, Lun-Lin and Xu, Yuan-Feng and Chen, Wen-Ya and Wang, Wei-Wei and Wang, Li-Hui},
title = {The gut microbiota metabolite butyrate mitigates MPTP / MPP + ‐induced Parkinson's disease by inhibiting the JAK2 / STAT3 signaling pathway},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2023},
volume = {39},
number = {10},
pages = {1002--1010},
doi = {10.1002/kjm2.12745}
}
EUVIMED